Europe Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2029

Description

List of Tables

The Europe syndromic multiplex diagnostic market is projected to register a CAGR of 8.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2020, and the forecast period is 2022 to 2029.

Market Segmentation:

Europe Syndromic Multiplex Diagnostic Market, By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others), Country (Germany, France ,U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium Rest of Europe) - Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of Europe syndromic multiplex diagnostic market are:

Increase in prevalence of infectious diseases

Increasing demand of fast and accurate diagnostic results

Market Players:

The major companies which are dealing in the Europe syndromic multiplex diagnostic are listed below:

BioFire Diagnostics (A Subsidiary of bioMerieux SA)

Seegene Inc.

Luminex Corporation. A DiaSorin Company

F. Hoffmann-La Roche Ltd

Bio-Rad Laboratories, Inc.

Cepheid (A Subsidiary of Danaher)

QIAGEN

Abbott

Hologic, Inc.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

Biocartis

QuantuMDx Group Ltd.

Bosch Healthcare Solutions GmbH (A Subsidiary of Robert Bosch GmbH)

Prominex Inc.

Curetis (A Subsidiary of OpGen, Inc.)

1 INTRODUCTION 27

1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 27
1.4 LIMITATIONS 29
1.5 MARKETS COVERED 29

2 MARKET SEGMENTATION 32

2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 CURRENCY AND PRICING 34
2.5 DBMR TRIPOD DATA VALIDATION MODEL 35
2.6 MULTIVARIATE MODELLING 38
2.7 PRODUCT AND SERVICES LIFELINE CURVE 38
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.9 DBMR MARKET POSITION GRID 40
2.10 MARKET END USER COVERAGE GRID 41
2.11 VENDOR SHARE ANALYSIS 42
2.12 SECONDARY SOURCES 43
2.13 ASSUMPTIONS 43

3 EXECUTIVE SUMMARY 44

4 PREMIUM INSIGHTS 46

4.1 PESTEL ANALYSIS 48
4.2 PORTER'S FIVE FORCES 49
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021) 50

5 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 51

6 MARKET OVERVIEW 54

6.1 DRIVERS 56
- 6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 56
- 6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 57
- 6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 58
- 6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 58
6.2 RESTRAINTS 59
- 6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 59
- 6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 59
6.3 OPPORTUNITIES 60
- 6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 60
- 6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE 60
- 6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS 62
6.4 CHALLENGES 63
- 6.4.1 PRODUCT RECALLS 63
- 6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 63

7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES 64

7.1 OVERVIEW 65
7.2 REAGENTS & CONSUMABLES 68
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES 68
7.4 SERVICES 69

8 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 71

8.1 OVERVIEW 72
8.2 VIRAL 75
- 8.2.1 CORONAVIRUS 76
- 8.2.2 INFLUENZA VIRUS 76
- 8.2.3 ADENOVIRUS 76
- 8.2.4 RHINOVIRUS 76
- 8.2.5 ROTAVIRUS 76
- 8.2.6 OTHERS 76
8.3 BACTERIAL 77
- 8.3.1 PNEUMONIAE 78
- 8.3.2 BORDETELLA PERTUSSIS 78
- 8.3.3 STAPHYLOCOCCUS 78
- 8.3.4 OTHERS 78
8.4 PARASITES 78
8.5 FUNGAL 79

9 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 81

9.1 OVERVIEW 82
9.2 RESPIRATORY INFECTIONS 85
9.3 GASTROENTERITIS 86
9.4 SEXUALLY TRANSMITTED INFECTIONS 86
9.5 SEPSIS 87
9.6 MENINGITIS 88
9.7 OTHERS 89

10 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 91

10.1 OVERVIEW 92
10.2 RESPIRATORY PANEL 95
10.3 GI-ENTERIC PANEL 95
10.4 SEXUALLY TRANSMITTED DISEASE PANEL 96
10.5 BLOOD-SEPSIS PANEL 97
10.6 MENINGITIS PANEL 98
10.7 OTHERS 99

11 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 100

11.1 OVERVIEW 101
11.2 HOSPITALS 104
11.3 CLINICAL LABORATORIES 104
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 105
11.5 RESEARCH INSTITUTES 106
11.6 OTHERS 107

12 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION 108

12.1 EUROPE 109
- 12.1.1 GERMANY 116
- 12.1.2 U.K. 119
- 12.1.3 FRANCE 122
- 12.1.4 ITALY 125
- 12.1.5 SPAIN 128
- 12.1.6 NETHERLANDS 131
- 12.1.7 SWITZERLAND 134
- 12.1.8 RUSSIA 137
- 12.1.9 BELGIUM 140
- 12.1.10 TURKEY 143
- 12.1.11 REST OF EUROPE 146

13 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 147

13.1 COMPANY SHARE ANALYSIS: EUROPE 147

14 SWOT ANALYSIS 148

15 COMPANY PROFILE 149

15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMERIEUX SA) 149
- 15.1.1 COMPANY SNAPSHOT 149
- 15.1.2 REVENUE ANALYSIS 149
- 15.1.3 COMPANY SHARE ANALYSIS 150
- 15.1.4 PRODUCT PORTFOLIO 150
- 15.1.5 RECENT DEVELOPMENTS 151
15.2 F. HOFFMANN-LA ROCHE LTD 152
- 15.2.1 COMPANY SNAPSHOT 152
- 15.2.2 REVENUE ANALYSIS 152
- 15.2.3 COMPANY SHARE ANALYSIS 153
- 15.2.4 PRODUCT PORTFOLIO 153
- 15.2.5 RECENT DEVELOPMENT 154
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY 155
- 15.3.1 COMPANY SNAPSHOT 155
- 15.3.2 RECENT FINANCIALS 155
- 15.3.3 COMPANY SHARE ANALYSIS 156
- 15.3.4 PRODUCT PORTFOLIO 156
- 15.3.5 RECENT DEVELOPMENT 157
15.4 CEPHEID (A SUBSIDIARY OF DANAHER) 158
- 15.4.1 COMPANY SNAPSHOT 158
- 15.4.2 RECENT FINANCIALS 158
- 15.4.3 COMPANY SHARE ANALYSIS 159
- 15.4.4 PRODUCT PORTFOLIO 159
- 15.4.5 RECENT DEVELOPMENTS 160
15.5 QIAGEN 161
- 15.5.1 COMPANY SNAPSHOT 161
- 15.5.2 RECENT FINANCIALS 161
- 15.5.3 COMPANY SHARE ANALYSIS 162
- 15.5.4 PRODUCT PORTFOLIO 162
- 15.5.5 RECENT DEVELOPMENT 162
15.6 ABBOTT 163
- 15.6.1 COMPANY SNAPSHOT 163
- 15.6.2 REVENUE ANALYSIS 163
- 15.6.3 PRODUCT PORTFOLIO 164
- 15.6.4 RECENT DEVELOPMENT 164
15.7 AKONNI BIOSYSTEMS, INC. 165
- 15.7.1 COMPANY SNAPSHOT 165
- 15.7.2 PRODUCT PORTFOLIO 165
- 15.7.3 RECENT DEVELOPMENT 165
15.8 APPLIED BIOCODE, INC. 166
- 15.8.1 COMPANY SNAPSHOT 166
- 15.8.2 PRODUCT PORTFOLIO 166
- 15.8.3 RECENT DEVELOPMENTS 167
15.9 BD 168
- 15.9.1 COMPANY SNAPSHOT 168
- 15.9.2 REVENUE ANALYSIS 168
- 15.9.3 PRODUCT PORTFOLIO 169
- 15.9.4 RECENT DEVELOPMENTS 169
15.10 BIOCARTIS 170
- 15.10.1 COMPANY SNAPSHOT 170
- 15.10.2 REVENUE ANALYSIS 170
- 15.10.3 PRODUCT PORTFOLIO 171
- 15.10.4 RECENT DEVELOPMENT 171
15.11 BIO-RAD LABORATORIES, INC. 172
- 15.11.1 COMPANY SNAPSHOT 172
- 15.11.2 REVENUE ANALYSIS 172
- 15.11.3 PRODUCT PORTFOLIO 173
- 15.11.4 RECENT DEVELOPMENT 173
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 174
- 15.12.1 COMPANY SNAPSHOT 174
- 15.12.2 REVENUE ANALYSIS 174
- 15.12.3 PRODUCT PORTFOLIO 175
- 15.12.4 RECENT DEVELOPMENT 175
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.) 176
- 15.13.1 COMPANY SNAPSHOT 176
- 15.13.2 RECENT FINANCIALS 176
- 15.13.3 PRODUCT PORTFOLIO 177
- 15.13.4 RECENT DEVELOPMENTS 177
15.14 HOLOGIC, INC. 178
- 15.14.1 COMPANY SNAPSHOT 178
- 15.14.2 RECENT FINANCIALS 178
- 15.14.3 PRODUCT PORTFOLIO 179
- 15.14.4 RECENT DEVELOPMENT 179
15.15 MIRXES PTE LTD. 180
- 15.15.1 COMPANY SNAPSHOT 180
- 15.15.2 PRODUCT PORTFOLIO 180
- 15.15.3 RECENT DEVELOPMENT 180
15.16 NANOMIX, INC. 181
- 15.16.1 COMPANY SNAPSHOT 181
- 15.16.2 PRODUCT PORTFOLIO 181
- 15.16.3 RECENT DEVELOPMENT 181
15.17 PROMINEX INC. 182
- 15.17.1 COMPANY SNAPSHOT 182
- 15.17.2 PRODUCT PORTFOLIO 182
- 15.17.3 RECENT DEVELOPMENT 182
15.18 QUANTUMDX GROUP LTD. 183
- 15.18.1 COMPANY SNAPSHOT 183
- 15.18.2 PRODUCT PORTFOLIO 183
- 15.18.3 RECENT DEVELOPMENTS 183
15.19 SEEGENE INC. 184
- 15.19.1 COMPANY SNAPSHOT 184
- 15.19.2 REVENUE ANALYSIS 184
- 15.19.3 PRODUCT PORTFOLIO 185
- 15.19.4 RECENT DEVELOPMENTS 188
15.20 SIEMENS HEALTHCARE GMBH 189
- 15.20.1 COMPANY SNAPSHOT 189
- 15.20.2 RECENT FINANCIALS 189
- 15.20.3 PRODUCT PORTFOLIO 190
- 15.20.4 RECENT DEVELOPMENT 190
15.21 THERMOFISHER SCIENTIFIC INC. 191
- 15.21.1 COMPANY SNAPSHOT 191
- 15.21.2 RECENT FINANCIALS 191
- 15.21.3 PRODUCT PORTFOLIO 192
- 15.21.4 RECENT DEVELOPMENT 192

16 QUESTIONNAIRE 193

17 RELATED REPORTS 196

LIST OF TABLES

TABLE 1 COST OF THE PRODUCT 51
TABLE 2 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION) 59
TABLE 3 EUROPE REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 60
TABLE 4 EUROPE INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 61
TABLE 5 EUROPE SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 62
TABLE 6 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 66
TABLE 7 EUROPE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 67
TABLE 8 EUROPE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 68
TABLE 9 EUROPE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 69
TABLE 10 EUROPE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 70
TABLE 11 EUROPE PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 71
TABLE 12 EUROPE FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 72
TABLE 13 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 76
TABLE 14 EUROPE RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 77
TABLE 15 EUROPE GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 78
TABLE 16 EUROPE SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 17 EUROPE SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 18 EUROPE MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 19 EUROPE OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 82
TABLE 20 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 86
TABLE 21 EUROPE RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 87
TABLE 22 EUROPE GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 88
TABLE 23 EUROPE SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 89
TABLE 24 EUROPE BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 90
TABLE 25 EUROPE MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 91
TABLE 26 EUROPE OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 91
TABLE 27 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 95
TABLE 28 EUROPE HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 96
TABLE 29 EUROPE CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 97
TABLE 30 EUROPE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 98
TABLE 31 EUROPE RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 98
TABLE 32 EUROPE OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 99
TABLE 33 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 105
TABLE 34 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 105
TABLE 35 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 105
TABLE 36 EUROPE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 106
TABLE 37 EUROPE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 106
TABLE 38 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 106
TABLE 39 UROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 107
TABLE 40 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 107
TABLE 41 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 108
TABLE 42 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 108
TABLE 43 GERMANY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 108
TABLE 44 GERMANY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 109
TABLE 45 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 109
TABLE 46 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 109
TABLE 47 GERMANY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 110
TABLE 48 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 111
TABLE 49 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 111
TABLE 50 U.K. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 111
TABLE 51 U.K. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 112
TABLE 52 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 112
TABLE 53 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 112
TABLE 54 U.K. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 113
TABLE 55 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 114
TABLE 56 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 114
TABLE 57 FRANCE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 114
TABLE 58 FRANCE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 115
TABLE 59 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 115
TABLE 60 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 115
TABLE 61 FRANCE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 116
TABLE 62 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 117
TABLE 63 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 117
TABLE 64 ITALY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 117
TABLE 65 ITALY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 118
TABLE 66 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 118
TABLE 67 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 118
TABLE 68 ITALY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 119
TABLE 69 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 120
TABLE 70 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 120
TABLE 71 SPAIN VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 120
TABLE 72 SPAIN BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 121
TABLE 73 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 121
TABLE 74 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 121
TABLE 75 SPAIN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 122
TABLE 76 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 123
TABLE 77 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 123
TABLE 78 NETHERLANDS VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 123
TABLE 79 NETHERLANDS BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 124
TABLE 80 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 124
TABLE 81 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 124
TABLE 82 NETHERLANDS SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 125
TABLE 83 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 126
TABLE 84 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 126
TABLE 85 SWITZERLAND VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 126
TABLE 86 SWITZERLAND BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 127
TABLE 87 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 127
TABLE 88 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 127
TABLE 89 SWITZERLAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 128
TABLE 90 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 129
TABLE 91 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 129
TABLE 92 RUSSIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 129
TABLE 93 RUSSIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 130
TABLE 94 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 130
TABLE 95 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 130
TABLE 96 RUSSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 131
TABLE 97 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 132
TABLE 98 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 132
TABLE 99 BELGIUM VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 132
TABLE 100 BELGIUM BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 133
TABLE 101 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 133
TABLE 102 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 133
TABLE 103 BELGIUM SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 134
TABLE 104 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 135
TABLE 105 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 135
TABLE 106 TURKEY VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 135
TABLE 107 TURKEY BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 136
TABLE 108 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 136
TABLE 109 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 136
TABLE 110 TURKEY SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 137
TABLE 111 REST OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 138

LIST OF FIGURES

FIGURE 1 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 22
FIGURE 2 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION 25
FIGURE 3 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS 26
FIGURE 4 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 27
FIGURE 5 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 27
FIGURE 6 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 29
FIGURE 7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 30
FIGURE 8 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID 31
FIGURE 9 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 32
FIGURE 10 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 35
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD 36
FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029 36
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 37
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 45
FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA 46
FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE 47
FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019 51
FIGURE 18 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021 55
FIGURE 19 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION) 56
FIGURE 20 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029) 56
FIGURE 21 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE 57
FIGURE 22 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021 62
FIGURE 23 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION) 63
FIGURE 24 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029) 63
FIGURE 25 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE 64
FIGURE 26 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021 72
FIGURE 27 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION) 73
FIGURE 28 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029) 73
FIGURE 29 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE 74
FIGURE 30 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021 82
FIGURE 31 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION) 83
FIGURE 32 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029) 83
FIGURE 33 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE 84
FIGURE 34 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021 91
FIGURE 35 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION) 92
FIGURE 36 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029) 92
FIGURE 37 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 93
FIGURE 38 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021) 100
FIGURE 39 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021) 101
FIGURE 40 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029) 101
FIGURE 41 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029) 102
FIGURE 42 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029) 102
FIGURE 43 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%) 137